Search Results for: cancer stem cells

Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates

stem cells for MS

For about as long as I’ve been writing The Niche, people have been asking about stem cells for MS. There’s a huge need for new therapies. While a chemo-based approach with autologous hematopoietic stem cell transplantation (HSCT) looks to work for certain cases of multiple sclerosis (although not yet approved in the US), other cell […]

Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates Read More »

Some CAR-T may very rarely cause new cancers

CAR-T, CAR-T cancer

The FDA issued a statement this week that there have been reports of new cases of blood cancer after patients received CAR-T therapies. The FDA specifically mentions T cell malignancies. New cancers in rare cases? In the announcement, FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell

Some CAR-T may very rarely cause new cancers Read More »

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als

clonal selection

Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als Read More »

Weekly reads: late Macchiarini retractions, stem cells & Lululemon

Paolo-Macchiarini

Paolo Macchiarini is one of a small group of people in the stem cell universe whose misconduct has blown up in the press. Piero Anversa, Haruko Obokata, Hwang Woo-Suk, and some operators in the unproven stem cell clinic sphere come to mind. Macchiarini published quite a few seriously problematic papers, some of which just hung

Weekly reads: late Macchiarini retractions, stem cells & Lululemon Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Weekly reads: big Retraction Watch news, stem cells & metastasis, an FDA approval, Iowa AG sues clinic

Retraction watch

Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think

Weekly reads: big Retraction Watch news, stem cells & metastasis, an FDA approval, Iowa AG sues clinic Read More »

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors

stem cell therapy

Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »

Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s

Knoepfler lab stem cells

Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was

Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS

stem cell research

It’s great finding stem cell videos on YouTube that are either excellent research talks or provide important information. I recently found one such video by Shiri Gur-Cohen, which I included below. Interesting data there and Shiri is such a compelling speaker. She also won The Niche image contest one year with a cool microscopy pic

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS Read More »

Stem cell therapy cost in 2024: data & analysis

stem cell therapy cost

How much does stem cell therapy cost in 2024? How have prices changed? To authoritatively answer these questions now we need data from the present and past along with expert perspectives. Some surprises come up in this new analysis. In this article Intro  | Stem Cell Therapy Cost: $10,000-$20,000 | Why do stem cells cost so much?

Stem cell therapy cost in 2024: data & analysis Read More »